Trials / Terminated
TerminatedNCT02372409
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 3 Years – 21 Years
- Healthy volunteers
- Not accepted
Summary
By employing a combination of advanced MRI techniques and correlative serum biomarkers of blood brain barrier (BBB) disruption, the investigators plan to develop a powerful, first of its kind clinical algorithm in pediatrics whereby the investigators can measure and identify the window of maximal BBB disruption post MLA to 1) allow for an alternative to surgery in incompletely resected tumors, 2) allow for optimal chemotherapeutic dosing to achieve the greatest benefits and the least systemic side effects and 3) distinguish subsequent tumor progression from long-term MLA treatment effects. Preliminary data in adult imaging studies have shown that the BBB disruption lasts for several weeks following treatment before returning to a low baseline. This pilot therapeutic study will provide preliminary validation in pediatric patients.
Conditions
- Glioma
- Pilocytic Astrocytoma
- Anaplastic Astrocytoma
- Glioblastoma
- Mixed Oligoastrocytoma
- Mixed Glioma
- Oligodendroglioma
- Optic Glioma
- Astrocytoma
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MRI-guided laser ablation | |
| DRUG | Doxorubicin | |
| DRUG | Etoposide | |
| DEVICE | Dynamic contrast-enhanced (DCE) MRI | |
| DEVICE | Dynamic susceptibility contrast (DSC) MRI |
Timeline
- Start date
- 2015-08-14
- Primary completion
- 2023-03-23
- Completion
- 2023-03-23
- First posted
- 2015-02-26
- Last updated
- 2024-11-01
- Results posted
- 2024-08-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT02372409. Inclusion in this directory is not an endorsement.